Idebenone (pronounced eye-deb-eh-known, trade names Catena, Raxone, Sovrima, among others) is a drug that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer’s disease and other cognitive defects. It is approved by the European Medicines Agency (EMA) for use in Leber’s hereditary optic neuropathy (LHON) and was designated an orphan drug in 2007.
\nNootropic effects and Alzheimer’s disease
\nResearch on idebenone as a potential therapy of Alzheimer’s disease have been inconsistent, but there may be a trend for a slight benefit. In May 1998, the approval for this indication was cancelled in Japan due to the lack of proven effects. In some European countries, the drug is available for the treatment of individual patients in special cases.
\nFriedreich’s ataxia (Sovrima)
\nPreliminary testing has been done in humans and found idebenone to be a safe treatment for Friedreich’s ataxia (FA), exhibiting a positive effect on cardiac hypertrophy and neurological function. The drug was approved for FA in Canada in 2008 under conditions including proof of efficacy in further clinical trials.
\nLeber’s hereditary optic neuropathy (Raxone)
\nLeber’s hereditary optic neuropathy (LHON) is a mitochondrially inherited (mother to all offspring) degeneration of retinal ganglion cells (RGCs) and their axons that leads to an acute or subacute loss of central vision; this affects predominantly young adult males.<\/p>\n
If RAXONE (idebenone) Tablets<\/strong> are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n Note:<\/strong> NEWS \/ UPDATES<\/strong><\/p>\n Raxone contains a substance called idebenone.<\/strong>\u00a0Idebenone is used to treat vision impairment in adults and adolescents with an eye disease called Leber\u2019s Hereditary Optic Neuropathy (LHON).
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/p>\n\n
RAXONE (idebenone) 150 mg film-coated tablets, for oral use.<\/h2>\n
\n– This eye problem is inherited \u2013 this means it runs in families.
\n– It is caused by a problem with your genes (called a \u201cgenetic mutation\u201d) that affects the ability of cells in the eye to produce the energy they need to work normally, so they become inactive.
\n– LHON can lead to loss of eyesight due to the inactivity of cells responsible for vision. Treatment with Raxone can restore the ability of cells to produce energy and so allow inactive eye cells to work again. This can lead to some improvement in lost eyesight.<\/p>\n